Navigation Links
Patheon to Feature its Complex Formulation Technologies Expertise at the Upcoming CPhI – P-MEC –ICSE – BioPh – Pharmatec – Medtec Japan – Conference
Date:4/14/2013

(PRWEB) April 14, 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will feature its wide range of complex formulation technologies for small molecules and biologics at the upcoming CPhI/ICSE conference in Tokyo, Japan.    

Dr. Kenji Yamada, Patheon, Advisor, will present “The Introduction of the Services of SoluPath™ and Quick to Clinic™” at 2:30 p.m. Japan Standard Time on April 26, 2013. SoluPath™ is an innovative and cost-effective service used to identify an optimal drug delivery system for compounds with poor bioavailability. In a recent case study, SoluPath™ improved bioavailability by four times in just three months. The Quick to Clinic™ program offers an accelerated delivery of Phase I clinical trial materials, guaranteeing finished product within four months of receipt of API.    

Patheon personnel will be at the upcoming CPhI/ICSE conference in Tokyo, Japan from April 24-26, 2013 and available to discuss how the company can actively support pharmaceutical and biotech companies achieve their objectives for both product development and manufacturing. The company will be exhibiting at Booth J-04 through the duration of the conference. To schedule a meeting in advance send an email to events(at)patheon(dot)com.

For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10626742.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
3. Patheon to Present at Informex USA
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. Patheon to Present at 2013 DCAT Week
6. Patheon to Present New Updates in Drug Formulation and Bioavailability
7. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
8. Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows
9. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Ellmans Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Ginkgo Bioworks, the organism company, announced today ... synthesis and assembly of DNA. The acquisition will ... DNA into Ginkgo,s automated organism engineering foundries, enabling ... new organism designs for application across a wide ... to significantly increase the world,s capacity to cost-effectively ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and ... ... that the global market is projected to reach $15,737 million by ... from 2016 to 2022. Omic technologies segment accounted ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, ... biopharmaceutical and medical device manufacturers and regulators, is proud to announce the worldwide ... email client designed to provide product vigilance departments with the flexibility and ease ...
Breaking Biology Technology:
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
Breaking Biology News(10 mins):